Loading…
← CockpitCompetitor Analysis › 300109.SZ Boai NKY Medical Holdings Ltd. Class AOpen in the cockpit ↗

Boai NKY Medical Holdings Ltd. Class A300109.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty

Henan-based holding company with pharmaceutical/medical-material interests; specific products not confirmed.

Momentum laggard 15
Mkt cap
$796M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$13.1M
20-day average traded
Fwd P/E
28.9×
forward earnings
ROIC−WACC
-4.3 pp
WACC 9.8%
Hurdle
+14 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥9.66
1D-0.1%
1W-10.5%
1M-16.8%
3M-28.9%
6M-39.7%
YTD-31.0%
1Y-30.9%
ATR %4.8%
52w lowhigh45.1% off high

What Boai NKY Medical does

Henan-based holding company with pharmaceutical/medical-material interests; specific products not confirmed.

Where it sits in the supply chain

  • Materials
  • Chemicals/pharma materials

Moat: none

Headquarters: Boai County, Henan, China · Employees: 1,186

Boai NKY Medical at a glance

Size Boai NKY Medical (300109.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $796M, the 2600th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.66 on 18 Nov 2026.

Performance Over six months the shares fell 39.7%, against -25.8% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue fell 16.6% over the last twelve months (peer median +7.2%); the operating margin is 14.8% (peer median 10.2%).

Valuation It trades at 28.9× forward earnings against a peer median of 18.5× (5th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.3 points below its cost of capital (9.8% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 76300109.SZ 62
Six months, rebased to 100: Boai NKY Medical against the median of its 20 peers (local-currency closes).

Boai NKY Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.21BCN¥1.17BCN¥1.60BCN¥1.58BCN¥1.48B
Revenue growth—-26%+1%+6%—
Gross profitCN¥577MCN¥518MCN¥726MCN¥867MCN¥674M
EBITDAn/aCN¥379MCN¥532MCN¥647MCN¥444M
Net incomeCN¥124MCN¥190MCN¥350MCN¥493MCN¥291M
Free cash flowCN¥149MCN¥118M-CN¥18.7MCN¥110M-CN¥11.3M
Capital expenditureCN¥174MCN¥220MCN¥275MCN¥378MCN¥266M
Total debtCN¥655MCN¥353MCN¥501MCN¥185MCN¥188M

Quarterly statements and history in the cockpit →

Boai NKY Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%CLEAN13143101002057600691603867301190GPRE3016834220002810300905603010300856301092002886000819300109.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Boai NKY Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%-10%0%+10%0×100×200×CLEAN3101002057600691300174GPRE002810300856301092002886300109.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Boai NKY Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%CLEAN3101002057600691300174603867GPRE4220002810300905300834300856002886300109.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Boai NKY Medical is the large dot.

Boai NKY Medical competitors and peer comparison

How Boai NKY Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Boai NKY Medical against its 20 peers (data as of 18 Nov 2026)
Measure300109.SZPeer medianRank in peer set
1-month return-16.8%-14.0%9th lowest of 21
6-month return-39.7%-25.8%3rd lowest of 20
Distance from 52-week high-45.1%-45.2%11th highest of 21
Revenue growth (TTM)-16.6%+7.2%4th lowest of 21
Operating margin14.8%10.2%6th highest of 21
Forward P/E28.9×18.5×5th most expensive of 13
Growth the price implies (Req g, 7 yrs)17.6%11.7%6th most demanding of 15
Growth delivered (Del g)+3.9%+8.0%4th lowest of 14
Hurdle (Req g minus delivered)+13.7 pp+6.1 pp6th most demanding of 14
ROIC minus cost of capital-4.3 pp-3.6 pp9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Boai NKY Medical 300109.SZChina$796M-40%-17%15%28.9×17.6%+3.9%
Clean Science & Technology CLEAN.NSIndia$794M-8%+5%26%27.8×33.0%+13.2%
China Petrochemical Development 1314.TWTaiwan$801M+6%-33%-18%n/an/an/a
Guangdong Sinoplast Adv Matl 301686.SZChina$802Mn/a+7%19%n/an/an/a
Toyobo 3101.TJapan$790M-12%+5%7%18.1×1.0%+4.6%
Sinosteel New Materials 002057.SZChina$803M-26%+13%9%11.6×11.3%+13.5%
Shanxi Lu'an Chemical Technology 600691.SSChina$788M-25%-14%-8%221.0×26.6%-11.2%
Fujian Yuanli Active Carbon 300174.SZChina$786M-19%+7%9%18.9×16.2%+10.1%
Zhejiang Xinhua Chemical 603867.SSChina$776M-35%+7%10%15.3×12.0%+4.9%
Jiujiang Shanshui Technology 301190.SZChina$820M+6%+54%19%n/an/an/a
Green Plains GPREUnited States$821M-26%-18%11%4.8×-8.6%+1.8%
Guangzhou Human New Material Science & Technology 301683.SZChina$824M-35%+20%38%n/a8.9%n/a
Riken Technos 4220.TJapan$769M+48%+6%11%10.5×-4.3%+8.3%
Shandong Head 002810.SZChina$826M-35%+16%21%13.4×-2.1%+7.9%
Poly Plastic Masterbatch (SuZhou) 300905.SZChina$827M-65%+10%11%n/a31.1%+17.2%
Zhejiang Wansheng 603010.SSChina$765M-41%+19%-26%n/an/an/a
Rastar Environmental Protection Materials 300834.SZChina$832M-37%-23%1%n/a41.3%0.0%
Nanjing COSMOS Chemical 300856.SZChina$758M-26%+12%12%35.7×3.6%+8.0%
Zhejiang Zhengguang Industrial 301092.SZChina$758M-6%-5%13%49.4×n/an/a
Shenzhen Wote Advanced Materials 002886.SZChina$838M-34%+10%4%63.1×29.8%+12.2%
Yueyang Xingchang Petro-Chemical 000819.SZChina$747M-22%+44%1%n/an/an/a

Questions

Which companies are Boai NKY Medical's closest peers?
The cockpit's peer set: Clean Science & Technology (CLEAN.NS), China Petrochemical Development (1314.TW), Guangdong Sinoplast Adv Matl (301686.SZ), Toyobo (3101.T), Sinosteel New Materials (002057.SZ), Shanxi Lu'an Chemical Technology (600691.SS), Fujian Yuanli Active Carbon (300174.SZ), Zhejiang Xinhua Chemical (603867.SS).
Is Boai NKY Medical expensive compared with its peers?
On forward p/e it trades at 28.9× against a peer median of 18.5×, 5th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Boai NKY Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -39.7% against -25.8% for the median peer; over one year -30.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.